𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of Temsirolimus Added to Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head-and-Neck Cancer: Results of the Randomized Phase 2 Maestro-HN Study

✍ Scribed by Seiwert, T.Y.; Adkins, D.; Worden, F.; Wade, J.L.; Hu, S.; Price, K.; Zavala, J.; Lussier, Y.; Vokes, E.E.; Cohen, E.E.W.

Book ID
122279092
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
54 KB
Volume
88
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

8517 Phase I results from an open-label,
8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)
✍ BrΓΌmmendorf, T.; Guigay, J.; MesΓ­a, R.; Trigo, J.; Keilholz, U.; Dittrich, C.; K πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 72 KB